121.86 -1.51 (-1.23%)
After hours: 5:00PM EDT
|Bid||108.12 x 1100|
|Ask||123.49 x 1300|
|Day's Range||116.63 - 123.74|
|52 Week Range||56.24 - 136.55|
|Beta (5Y Monthly)||1.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||130.20|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Bullish chart patterns on the KOMP ETF and its top holdings suggest that it could be an ideal time to increase exposure to innovative tech companies.
SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today that Douglas Devine has been appointed Chief Financial Officer (CFO), effective June 22, 2020. Mr. Devine will succeed Matthew Garrett, who has decided to step down from the role. Mr. Garrett has agreed to assist in a well-ordered transition of his CFO responsibilities and will remain at iRhythm in an advisory role for up to a year to assist with special projects.
Ladies and gentlemen, thank you for standing by, and welcome to the iRhythm Technologies, Inc. Q1 2020 earnings conference call. Joining me are Kevin King, CEO; Matthew Garrett, CFO; and Dan Wilson, EVP, strategy, corporate development and investor relations. Earlier today, iRhythm released financial results for the first quarter ended March 31, 2020.
IRHYTHM TECH (IRTC) delivered earnings and revenue surprises of 40.35% and 3.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN FRANCISCO, May 07, 2020 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today.
SAN FRANCISCO, April 29, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the first quarter 2020 after the close of trading on Thursday, May 7, 2020. iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed.
SAN FRANCISCO, April 29, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced its virtual platform to support patients and clinicians in the wake of COVID-19 by offering home enrollment for the company’s Zio XT and Zio AT heart monitoring devices. Since patients with heart conditions are a particularly vulnerable population for COVID-19 and should avoid unnecessary visits to a doctor’s office, they can receive and apply the device from the comfort of their homes.
SAN FRANCISCO, April 23, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the appointment of Renee Budig to its Board of Directors effective April 23, 2020. Ms. Budig was appointed as a Class II director and will also serve on the Audit Committee. “On behalf of the iRhythm team, I am delighted to welcome Renee to our Board of Directors,” said Kevin King, CEO.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
David Newman no longer wears a tie to work. “We thought that telemedicine would be a burden, but it hasn’t been,” says Newman, 39, an endocrinologist at Sanford Health. The coronavirus epidemic is catapulting telemedicine from the outskirts of health care to its core.
SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today provided an update on the impact the company is experiencing due to the COVID-19 pandemic and the steps the company is taking in response. The company is also providing a preliminary range for revenue for its first quarter 2020 and is withdrawing full-year 2020 guidance. “The COVID-19 pandemic has been an unprecedented challenge to the healthcare community and our society,” said Kevin King, CEO.
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
iRhythm Technologies, Inc. (NASDAQ:IRTC) came out with its annual results last week, and we wanted to see how the...
SAN FRANCISCO, Feb. 27, 2020 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today.
Pomerantz LLP is investigating claims on behalf of investors of iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (IRTC). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. The investigation concerns whether iRhythm and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
SAN FRANCISCO, Feb. 10, 2020 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today.
IRHYTHM TECH (IRTC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Global Kinetics Pty Ltd., a digital health company focused on the development and commercialization of the Personal KinetiGraph® (PKG®), the first FDA-cleared and CE-marked platform for the objective measurement of movement symptoms in the management of Parkinson’s disease, today announced the appointment of Matthew C. Garrett, an experienced financial executive in the life sciences industry, as an independent director to its Board of Directors. “We are delighted to welcome Matt to our Board,” said John Schellhorn, CEO of Global Kinetics Corporation.
SAN FRANCISCO, Dec. 30, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today.
SAN FRANCISCO, Dec. 23, 2019 -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced.
Getting everyone on board isn’t always easy. Whether out at a restaurant ordering a shared platter with friends, or choosing a song from a playlist, it can be challenging to reach an agreement with those around you, and mostly impossible to please everyone at the same time.Of course, there are exceptions to the rule, and even the analysts on Wall Street all reach the same conclusion at times. Common disagreements on whether a stock is over-sold or over-bought, are periodically put aside as a consensus is reached about one’s potential.The odds are even harder to beat when considering the future potential of stocks from the same sector, so when everyone is singing from the same hymn sheet, it’s time to take notice.With this in mind, we used TipRanks’ Analysts' Top Stocks tool to home in on 3 stocks in the same sector (healthcare in our case) which have received nothing but bullish shout outs in the last three months, and which, additionally, all have a Strong Buy consensus rating. Let’s get the lowdown.NextCure Inc (NXTC)This biotech, which develops new cancer drugs, has been turning heads on the Street recently.As is common in the sector, NextCure’s share price skyrocketed at the start of November following the release of promising data from early clinical trial results for its cancer treatment, NC318, an antibody targeting Siglec-15 (an immuno-suppressive protein of the tumor micro-environment). The news caused the share price to soar almost 250% in a single day. Roughly a week later, the stock crashed by over 50% in a session, following updated data which wasn’t quite as promising.These shenanigans are common in the volatile world of biotechs, and not much is to be deduced from the wild price swings following such early results. As it happens, in this case, NextCure’s pedigree is very strong.The company’s founder is Dr. Lieping Chen, Professor of Immunobiology at Yale University, and discoverer of the PD-L1/PD1 pathway, which showed that blocking the interaction between PD-1 and PD-L1 by monoclonal antibodies had a positive effect on the immune system’s ability to eliminate tumors.NextCure has other cancer treatment medicines in the pipeline, and BTIG’s Robert Hazlett sets out the bullish case for the recently listed biotech.The 5-star analyst noted, “NC318 has material promise as it modifies the activity of S15, a potent immunosuppressive protein, in the tumor microenvironment (TME). Normally S15 is expressed at very low levels, but in the TME, it is materially overexpressed, creating the potential for a meaninful immuno-oncology target, as it is present in 15-25% in NSCLC, TNBC, ovarian and head & neck cancers, providing NC318 with multi-billion dollar potential. NextCure is also employing its FIND-IO discovery platform toward developing other IO therapies.”Therefore, Hazlett initiated coverage on NextCure with a Buy rating, and set a price target of $61. As share prices surged at the end of last week, the upside potential comes in at a modest 4%. (To watch Hazlett’s track record, click here)Three other analysts tracked over the last 3 months all rate NextCure as a Buy, which collectively adds up to a Strong Buy consensus rating. The fellow analysts are even more bullish than Hazlett, as the average price target of $68.75 implies potential upside of 17%. (See NextCure stock analysis on TipRanks) Axsome Therapeutics Inc (AXSM)On to the Street’s next promising healthcare choice, and we encounter a recurring theme. Axsome therapeutics is up by over 115% in the last week, following -you guessed it- positive trial data.The CNS (central nervous system) focused biotech, released results for its experimental anti-depression drug, AXS-05, showing the treatment met the primary endpoint in a Phase 3 clinical trial. Axsome plans to submit an application to the FDA for approval of the therapy in the second half of 2020.The positive results back up a previous phase 2 trial in which AXS-05 exhibited superior efficacy compared to Bupropion for both MDD (major depressive disorder) and smoking cessation.BTIG’s Robert Hazlett also covers Axsome and reminds investors of the company’s potential. “Taken together, these data show consistent, rapid, durable, and significant anti-depressant effects of AXS-05 and de-risk AXS-05 in MDD; with additional strong results, we also modestly reduce our discount for AXS-05 in treatment resistant depression (TRD) as well… Given AXS-05’s relatively clear path to approval, consistent efficacy profile, and oral delivery, we now formally include M&A exit optionality into our valuation… We believe there is evidence that AXS-05’s broad activity at multiple CNS receptors (NMDA, Sigma-1, others) has the potential to support its use in multiple large CNS indications with peak sales potential of several billion dollars,” he said.Therefore, Hazlett reiterated his Buy recommendation on Axsome, alongside a price target of $97.A full house of 9 Buys bestows on Axsome Strong Buy status. As the average price target stands at $123.50, there is further room for growth in the shape of 23%. (See Axsome stock analysis on TipRanks) iRhythm Technologies (IRTC)Digital healthcare company, iRhythm Technologies, has had a poor 2019, with its share price losing 12% year-to-date. Looking at the bigger picture, though, the cardiac device specialist still has a lot going for it.The company’s flagship product, Zio, is a wearable patch that detects cardiac symptoms and has gained quick adoption due to ease of use and accurate data readings.iRhythm’s marketing strategy of getting a foot in the door at doctors’ offices to set up new accounts, has seen use of the Zio XT patch in diagnostic situations rise from 10% of accounts at the end of 2016 to 70% by 2018’s close. A further addition of sales representatives indicates the company will see out 2019 with as many as 140 sales reps, compared to 110 at the end of 2018, and significantly more than 2017’s 86.RBC’s Brandon Henry is with the bulls on iRhythm. The 4-star analyst noted, “We believe IRTC’s core business will continue to perform well, led by new sales rep adds, increased sales rep productivity, the full commercial launch of Zio AT (which should drive additional XT sales), and continued penetration in large integrated hospitals.”To this end, Henry reiterated an Outperform rating on the medical instrument maker, alongside a price target of $109. Should the target be met, gains of almost 79% could be in line over the next 12 months. (To watch Henry’s track record, click here)Where does the Street stand on iRhythm? The Street agrees with Henry. The cardiac device developer has a Strong Buy consensus rating, based on 3 Buy recommendations. The average target price adds 50 cents to the RBC analyst’s target and comes in at $109.50, implying handsome upside potential of 80%. (See iRhythm's price targets and analyst ratings on TipRanks)
SAN FRANCISCO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (IRTC) today announced its participation in a new, randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals), sponsored by the Bristol-Myers Squibb-Pfizer Alliance (the Alliance). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]